Marshall Wace North America L.P. purchased a new position in The Medicines Company (NASDAQ:MDCO) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 138,644 shares of the company’s stock, valued at approximately $5,268,000. Marshall Wace North America L.P. owned 0.20% of The Medicines as of its most recent filing with the SEC.

Other large investors also recently bought and sold shares of the company. Municipal Employees Retirement System of Michigan boosted its stake in The Medicines by 0.3% in the first quarter. Municipal Employees Retirement System of Michigan now owns 15,850 shares of the company’s stock worth $775,000 after buying an additional 50 shares during the last quarter. US Bancorp DE boosted its stake in The Medicines by 1.7% in the first quarter. US Bancorp DE now owns 3,413 shares of the company’s stock worth $167,000 after buying an additional 58 shares during the last quarter. First Mercantile Trust Co. boosted its stake in The Medicines by 2.5% in the second quarter. First Mercantile Trust Co. now owns 4,767 shares of the company’s stock worth $181,000 after buying an additional 114 shares during the last quarter. Envestnet Asset Management Inc. boosted its stake in The Medicines by 5.1% in the first quarter. Envestnet Asset Management Inc. now owns 2,496 shares of the company’s stock worth $122,000 after buying an additional 120 shares during the last quarter. Finally, Old West Investment Management LLC boosted its stake in The Medicines by 2.5% in the first quarter. Old West Investment Management LLC now owns 10,752 shares of the company’s stock worth $525,000 after buying an additional 259 shares during the last quarter.

The Medicines Company (NASDAQ:MDCO) opened at 38.74 on Wednesday. The Medicines Company has a 12-month low of $30.80 and a 12-month high of $55.95. The company’s 50-day moving average is $37.37 and its 200 day moving average is $44.36. The stock’s market capitalization is $2.79 billion.

The Medicines (NASDAQ:MDCO) last announced its earnings results on Wednesday, August 9th. The company reported ($5.52) EPS for the quarter, missing the Zacks’ consensus estimate of ($1.29) by $4.23. The firm had revenue of $18.74 million during the quarter, compared to the consensus estimate of $29.64 million. The Medicines had a negative return on equity of 137.20% and a negative net margin of 670.46%. The business’s revenue for the quarter was down 65.8% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.62) earnings per share. On average, equities research analysts expect that The Medicines Company will post ($9.57) earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: “Marshall Wace North America L.P. Purchases Shares of 138,644 The Medicines Company (MDCO)” was posted by Watch List News and is owned by of Watch List News. If you are reading this news story on another website, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright law. The legal version of this news story can be read at https://www.watchlistnews.com/marshall-wace-north-america-l-p-purchases-shares-of-138644-the-medicines-company-mdco/1531162.html.

A number of research firms have commented on MDCO. Chardan Capital restated a “buy” rating and issued a $85.00 price target (up from $80.00) on shares of The Medicines in a report on Tuesday. ValuEngine cut shares of The Medicines from a “sell” rating to a “strong sell” rating in a report on Saturday, May 20th. Citigroup Inc. reduced their price target on shares of The Medicines from $45.00 to $44.00 and set a “neutral” rating for the company in a report on Monday, August 14th. Cowen and Company restated a “buy” rating and issued a $54.00 price target (down from $61.00) on shares of The Medicines in a report on Thursday, August 10th. Finally, Oppenheimer Holdings, Inc. assumed coverage on shares of The Medicines in a report on Monday, May 22nd. They issued a “market perform” rating and a $50.00 price target for the company. One analyst has rated the stock with a sell rating, two have given a hold rating and nine have issued a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average target price of $54.00.

About The Medicines

The Medicines Company is a global biopharmaceutical company. The Company is focused on advancing the treatment of acute and intensive care patients through the delivery of medicines to the hospital marketplace around the world. It markets Angiomax (bivalirudin), Ionsys (fentanyl iontophoretic transdermal system), Minocin (minocycline) for injection and Orbactiv (oritavancin).

Institutional Ownership by Quarter for The Medicines (NASDAQ:MDCO)

Receive News & Ratings for The Medicines Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for The Medicines Company and related companies with Analyst Ratings Network's FREE daily email newsletter.